Celltrion USA’s Humira Biosimilar Now Available at Low Wholesale Acquisition Cost
Celltrion USA announced today that adalimumab-aaty, the company’s high-concentration (100 mg/mL) and citrate-free formulation biosimilar to Humira (adalimumab), is now available at a low wholesale acquisition cost (WAC). Adalimumab-aaty will be priced as WAC list price at an 85% discount to the current WAC list price of Humira. Adalimumab-aaty is also available from Celltrion USA […]